Draft guidelines on organ transplants call for more thorough donor screening and more advanced organ testing to help protect patients from infections transmitted through transplants. The draft from the Centers for Disease Control and Prevention (CDC)Â concerns infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). It recommends adding HBV and HCV to the list of organisms to be screened.
From 2007 to 2010, CDC participated in more than 200 investigations of suspected unexpected transmission of HIV, HBV, and HCV through transplants. Of those that were confirmed, some led to the death of the transplant recipient. To update standards for safe transplants, the CDC led a multidisciplinary group of transplant and infection prevention experts through a systematic review of the best available evidence. The result includes recommendations based on this review.
The full draft guidelines can be found at www.regulations.gov and the CDC encourages review and response during the 60day comment period. The document is titled "Draft 2011 Public Health Service (PHS) Guideline for Reducing Transmission of HIV, HBV, and HCV through Solid Organ Transplantation." The CDC was the lead scientific agency in writing the report; the PHS is responsible for guidelines that address the transmission of communicable diseases through transplantation to regulatory requirements.
"Our first priority must be patient safety. These recommendations will save lives and reduce unintended disease in organ recipients," says Matthew J. Kuehnert, MD, director of CDCs Office of Blood, Organ, and Other Tissue Safety Office. "The guideline will help patients and their doctors have information they need to fully weigh risks and benefits of transplanting a particular organ."
Major changes from the 1994 PHS Guideline include:
- Focusing only on solid organs and vessel conduits, and not other tissues. The Food and Drug Administration has implemented more comprehensive regulations for tissue and semen donors, leaving the focus of the 2011 Draft PHS Guideline on organ safety.
- A revised set of donor risk factors that can give clinicians a more thorough picture about possible risks associated with donors organs.
- Recommending updated, more sensitive laboratory tests for organs. The ultimate goal is to ensure organ recipients are informed of risk to the extent possible and protected from unintentional infection transmission.
- Recommending HBV and HCV screening, in addition to HIV. Previous recommendations include only HIV.
"We recognize that organ demand is much greater than availability, and that organ transplantation is often a lifesaving procedure," says Kuehnert. "This guideline will assist the transplant community in ensuring that each patient is protected against unexpected diseases from the organ they so desperately need."
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.